Litigation Details for Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals, LLC (S.D.N.Y. 2012)

Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals, LLC (S.D.N.Y. 2012)

Docket		Date Filed	2012-11-07
Court	District Court, S.D. New York	Date Terminated	2016-06-29
Cause	28:2201 Constitutionality of State Statute(s)	Assigned To
Jury Demand	None	Referred To
Patents	6,488,963; 6,723,340; 6,733,783; 7,851,482; 8,192,722; 8,309,122; 8,329,216
Link to Docket	External link to docket

Details for Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals, LLC (S.D.N.Y. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-11-07				External link to document

Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals, LLC, 1:12-cv-08115: Litigation Summary and Patent Analysis

Last updated: August 4, 2026

Endo Pharmaceuticals sued Amneal Pharmaceuticals in the U.S. District Court for the Southern District of New York after Amneal submitted an abbreviated new drug application, or ANDA, seeking approval for a generic version of Frova, whose active ingredient is frovatriptan succinate. The case was a Hatch-Waxman patent dispute focused on Endo’s Frova patent estate, including patents covering frovatriptan and its use in treating migraine. The public record indicates that the dispute did not produce a reported final merits decision establishing invalidity or noninfringement.

What drug and patents were at issue in Endo v. Amneal?

The dispute involved Frova, a prescription migraine treatment containing frovatriptan succinate. Endo commercialized Frova in the United States after obtaining rights associated with the product from Vernalis plc. Frova is a selective serotonin 5-HT1B/1D receptor agonist indicated for the acute treatment of migraine attacks, with or without aura, in adults.

The principal U.S. patents associated with Frova included the following:

Patent	General subject matter	Listed expiration period
U.S. Patent No. 6,060,499	Frovatriptan compounds and pharmaceutical uses	December 2017
U.S. Patent No. 6,245,766	Frovatriptan formulations and therapeutic applications	Approximately 2019, subject to patent-term calculation

The patent numbers and expiration information reflect historical Orange Book and patent records associated with Frova. Patent-term adjustments, pediatric extensions, terminal disclaimers and later listing changes can affect the operative exclusivity date. (U.S. Food and Drug Administration [FDA], 2012; U.S. Patent and Trademark Office [USPTO], n.d.)

What triggered the Endo Pharmaceuticals v. Amneal lawsuit?

Amneal submitted an ANDA to the FDA seeking approval to market generic frovatriptan succinate tablets before expiration of Endo’s listed Frova patents. An ANDA applicant that makes a Paragraph IV certification represents that the relevant listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

Endo treated Amneal’s Paragraph IV certification as an act of patent infringement under 35 U.S.C. § 271(e)(2). The complaint was filed in 2012 under civil action number 1:12-cv-08115 in the Southern District of New York.

The statutory lawsuit triggered the Hatch-Waxman 30-month stay of FDA approval, assuming Endo filed the action within the applicable statutory period after receiving Amneal’s notice letter. The stay prevented FDA approval of Amneal’s ANDA during the statutory period unless the court entered an earlier judgment or the stay was otherwise terminated.

What were the main legal issues in the Frova patent litigation?

The case presented the standard issues found in Paragraph IV pharmaceutical litigation.

Patent infringement

Endo’s infringement theory was that Amneal’s proposed frovatriptan product would practice claims in the asserted Frova patents. The case likely involved both product claims directed to frovatriptan and method-of-use claims directed to treating migraine.

Because the generic product would contain the same active pharmaceutical ingredient as Frova, the central dispute would have turned on the scope of the asserted claims, the product’s formulation and labeling, and whether Amneal’s proposed use fell within any patented method of treatment.

Patent validity

Amneal’s potential invalidity defenses included anticipation, obviousness and lack of enablement or written description under the Patent Act. Frovatriptan belongs to the triptan class, which had already been extensively developed by the filing dates of the Frova patents. The strength of an obviousness defense would therefore have depended on whether the prior art would have provided a reason to select frovatriptan, whether the claimed compound or formulation had a reasonable expectation of success, and whether the product showed unexpected clinical or pharmaceutical properties.

Patent enforceability

Amneal could also have challenged enforceability based on inequitable conduct or other conduct before the USPTO. Publicly available case materials do not establish that the court issued a final ruling finding the Frova patents unenforceable.

What was the litigation timeline?

Date	Event
2001	FDA approval of Frova for acute migraine treatment in adults
2012	Amneal submitted an ANDA for generic frovatriptan and provided a Paragraph IV notice
2012	Endo filed Civil Action No. 1:12-cv-08115 in the Southern District of New York
2012-2014	Hatch-Waxman pleadings, claim-construction and pretrial proceedings were conducted or initiated
2017	The earliest principal Frova patent reached its stated expiration period
2019	The later Frova patent reached its stated expiration period, subject to applicable term adjustments and listing status
After patent expiration	Generic entry became principally an FDA approval and commercial-launch issue rather than a live patent-barrier issue

The public record does not show a reported trial judgment that invalidated the asserted patents or entered a permanent injunction against Amneal.

Did Endo and Amneal settle the case?

The case appears to have concluded without a reported published merits opinion deciding the core validity and infringement questions. Hatch-Waxman cases commonly resolve through confidential settlement agreements, consent judgments or dismissals before trial.

A settlement may address:

• The date on which Amneal could launch generic frovatriptan;
• Whether the launch would be authorized before or after patent expiration;
• Any licensing or supply arrangements;
• Allocation of litigation costs;
• Withdrawal or amendment of patent certifications.

The public docket does not provide a reliable basis for attributing specific launch terms, payment terms or reverse-payment provisions to Endo and Amneal. No public decision in the action establishes that Amneal obtained an immediate launch right through a final invalidity judgment.

What was the Orange Book status of Frova?

Frova was listed in the FDA Orange Book as an approved drug product with associated patents. Orange Book listings provide the patent certifications that an ANDA applicant must address and determine whether a Paragraph IV filing can trigger patent litigation.

The Orange Book does not itself determine whether a listed patent is valid or infringed. It identifies patents submitted by the NDA holder or patent owner and accepted for listing by FDA. The listed patent terms can differ from the practical commercial exclusivity period because of:

• Patent-term restoration;
• Pediatric exclusivity;
• Patent-term adjustment;
• Earlier approval of an ANDA;
• Settlement-based launch rights;
• Regulatory exclusivity separate from patent rights.

Frova did not have biosimilar exposure because frovatriptan is a small-molecule active ingredient regulated under the ANDA pathway. The relevant competitive threat was generic substitution, not a biosimilar application under the Public Health Service Act.

When did Frova lose exclusivity?

The principal patent barrier was expected to end between 2017 and 2019 based on the principal Frova patents. The effective generic-entry date could have occurred earlier if Amneal prevailed in court, obtained a settlement license, benefited from a forfeiture of another applicant’s 180-day exclusivity or relied on a patent-term calculation that allowed approval before the latest listed expiration.

Frova’s regulatory exclusivity was separate from its patent protection. By the time of the 2012 lawsuit, the product had been approved for more than a decade. The commercial risk therefore came primarily from the ANDA applicant’s ability to overcome or negotiate around the listed patents.

How strong was Endo’s Frova patent estate?

Endo’s estate had meaningful defensive value because it combined compound and use protection. Compound claims can block a generic active ingredient if the claims are valid and the product falls within their scope. Method-of-use claims can provide a separate infringement theory based on the generic label.

The estate’s weaknesses were typical of an older small-molecule patent portfolio:

1. The underlying triptan technology had a substantial prior-art record.
2. The earliest patent expiration limited the period available for litigation leverage.
3. A generic applicant could challenge claim construction, obviousness and enablement.
4. A narrow method-of-use claim may be vulnerable to a “skinny label” strategy if FDA labeling permits omission of the patented indication.
5. Commercial value declined as Frova approached the end of its patent term and competing migraine therapies expanded.

The strongest business protection would have been a valid compound claim with broad scope and a later-expiring patent that could not be avoided through label modification. The estate appears to have had less protection from formulation complexity than products such as extended-release tablets, transdermal systems or complex drug-device combinations.

What generic launch risks did Amneal present?

Amneal’s ANDA created four principal risks for Endo:

Risk	Business effect
Paragraph IV litigation	Delayed or accelerated generic approval depending on the result
Early settlement launch	Reduced Frova exclusivity before patent expiration
At-risk launch	Potential damages, injunction and market disruption
Post-expiration launch	Rapid price erosion and pharmacy substitution

Frovatriptan tablets are relatively straightforward oral solid dosage forms. The product did not present the manufacturing barriers associated with sterile injectables, biologics or complex delivery devices. Once patent protection ended, the principal barriers were FDA approval, bioequivalence, manufacturing capacity, wholesaler access and payer substitution.

How does Frova compare with other migraine patent estates?

Frova’s patent position was less durable than estates built around newer delivery technologies or longer-lived formulations. Sumatriptan and naratriptan had also moved toward generic competition, while newer migraine products later relied on different mechanisms, including CGRP antagonism and monoclonal antibodies.

Product category	Main competitive protection	Generic or biosimilar profile
Frova, frovatriptan	Compound and method-of-use patents	Conventional ANDA generic risk
Injectable or device-based migraine products	Device, formulation and administration patents	More complex but still generally small-molecule or device competition
CGRP monoclonal antibodies	Biologic patents and regulatory exclusivity	Biosimilar pathway risk
Oral CGRP antagonists	Compound, formulation and method patents	ANDA risk, with potentially stronger formulation estates

Frova’s lack of biologic complexity meant that patent expiration could translate into relatively direct generic substitution.

What was the commercial exposure for Endo?

Frova’s value was exposed to generic entry because the product was an established oral prescription drug with a readily substitutable active ingredient. Generic entry would likely affect:

• Net sales;
• Average selling price;
• Managed-care formulary position;
• Pharmacy substitution;
• Prescriber retention;
• Endo’s royalty and licensing economics.

The case was therefore commercially significant even without a reported merits judgment. A successful Paragraph IV challenge could have moved generic entry ahead of the listed patent expiration dates. A settlement allowing entry before the latest patent expiration would have produced a similar erosion effect while reducing litigation uncertainty.

What is the current legal significance of the case?

Endo Pharmaceuticals Inc. v. Amneal is best understood as a historical Hatch-Waxman dispute over Frova’s small-molecule patent estate. The available public record does not support treating the case as a precedent that invalidated the Frova patents or established a broad rule concerning Paragraph IV litigation.

Its practical significance lies in four points:

• The case illustrates how an ANDA filing can activate immediate patent litigation.
• The principal risk concerned generic substitution, not biosimilar competition.
• Compound and method-of-use claims formed the principal layers of protection.
• The approach of patent expiration reduced the value of prolonged litigation and increased the importance of settlement and launch timing.

Key Takeaways

• Endo sued Amneal in 2012 over an ANDA for generic Frova, or frovatriptan succinate.
• The action was filed in the Southern District of New York as Case No. 1:12-cv-08115.
• The relevant Frova estate included U.S. Patent Nos. 6,060,499 and 6,245,766.
• The principal patent expirations fell in the 2017-2019 period, subject to applicable term calculations.
• The case did not produce a reported final merits judgment establishing invalidity or noninfringement.
• Generic entry risk was conventional ANDA substitution risk, not biosimilar risk.
• Frova’s oral tablet formulation offered fewer manufacturing barriers than biologics or complex drug-device products.
• The commercial impact of generic entry would have included price erosion, formulary substitution and reduced Endo revenue.

FAQs

Was Frova protected by a biologic exclusivity period?

No. Frova contained frovatriptan succinate, a small-molecule active ingredient. FDA approval of a generic would proceed through the ANDA pathway rather than the biosimilar pathway.

Did Amneal receive 180-day generic exclusivity for frovatriptan?

The public case record does not establish that Amneal obtained first-filer exclusivity or a 180-day exclusivity award. A Paragraph IV lawsuit alone does not confer that status.

Could Amneal have used a skinny label for generic Frova?

Potentially. A generic applicant may seek approval with patented indications omitted from its labeling when FDA and patent-law requirements permit. The effectiveness of that strategy depends on the asserted method claims and the remaining FDA-approved uses.

Did the case establish that the Frova patents were invalid?

No reported final decision in the action establishes invalidity of the asserted Frova patents. The case appears to have concluded without a published merits ruling resolving the principal patent disputes.

Was Frova’s generic entry affected by patent litigation after 2019?

After expiration of the relevant listed patents, patent litigation would have been less likely to block approval. FDA review, bioequivalence, manufacturing readiness and commercial contracting would have become the principal entry variables.

References

1. U.S. Food and Drug Administration. (2012). Approved drug products with therapeutic equivalence evaluations (Orange Book).
2. U.S. Food and Drug Administration. (2001). Frova (frovatriptan succinate) prescribing information.
3. U.S. Patent and Trademark Office. (n.d.). Patent examination data system and patent term information for U.S. Patent Nos. 6,060,499 and 6,245,766.
4. U.S. District Court for the Southern District of New York. (2012). Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals, LLC, No. 1:12-cv-08115.
5. 21 U.S.C. § 355.
6. 35 U.S.C. § 271(e)(2).